SCHEMBL4236338

SCHEMBL4236338

Cc1ccc2c(c1)c(C(=O)O)cn2-c1ccc2ccccc2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
KDM4E B2RXH2 3/20 0.44
HSD17B10 Q99714 1/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
NR1I2 O75469 1/20 0.40
AHR P35869 1/20 0.40
HCAR2 Q8TDS4 1/20 0.39
MAPT P10636 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MGAM O43451 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
HTR3A P46098 1/20 0.38
KDR P35968 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4239897 0.89 NPC1 (0.40) ALDH1A1KDM4EHSD17B10NPC1RAB9A
Hydrochloric Acid SCHEMBL4244278 0.88 NPC1 (0.40) ALDH1A1KDM4EHSD17B10NPC1RAB9A
SCHEMBL4236172 0.87 NR4A2 (0.45) ALDH1A1KDM4ENPC1RAB9AKMT2A
SCHEMBL4239984 0.85 NPC1 (0.49) ALDH1A1KDM4EHSD17B10NPC1RAB9A
SCHEMBL13855105 0.85 SLC9A1 (0.40) ALDH1A1NPC1RAB9AKMT2AMEN1
SCHEMBL4244306 0.83 NPC1 (0.38) ALDH1A1KDM4ENPC1RAB9AKMT2A
Hydrochloric Acid SCHEMBL4242177 0.82 NPC1 (0.38) ALDH1A1KDM4ENPC1RAB9AKMT2A
SCHEMBL4236274 0.75 PTGDR2 (0.48) ALDH1A1KDM4EHSD17B10KMT2AMEN1
SCHEMBL4242161 0.75 KMT2A (0.43) ALDH1A1KDM4EHSD17B10NPC1RAB9A
SCHEMBL4062265 0.73 NPC1 (0.45) ALDH1A1KDM4ENPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7531663-B2 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-05-12 US disclosed
US-20050026989-A1 3-Guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026989-A1 3-Guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them IDO1, IDO2, HTR3C ALDH1A1 963/4885KDM4E 1286/4885HSD17B10 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.